Sign in to view content

Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial

John W. Kitchens, MD

Video
Published 2021

Related

Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2022
Canadian Treat-and-Extend Analysis Trial With Ranibizumab in Patients With Neovascular AMD: CANTREAT Study 1-Year Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2018
Treatment Patterns and Visual and Health Function in Neovascular Age-Related Macular Degeneration (nAMD): Medicare Current Beneficiary Survey Analysis
Ferhina S Ali, MD, MPH
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more